Abiopharma

🔍 Brady Kelly (Executive)

Company: Seres Therapeutics, Inc. (MCRB)

Report Date: 2026-08-15

Detailed Transactions and Holdings:

• Acquired 181 shares of Common Stock (Direct)
  Date: 2026-08-15 | Code: M | equity_swap_involved: false | shares_owned_after: 8,743.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 64 shares of Common Stock at $4.55 per share (Direct)
  Date: 2026-08-17 | Code: S | equity_swap_involved: false | shares_owned_after: 8,679.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 90 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-15 | Code: M | equity_swap_involved: false | shares_owned_after: 179.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3
• Sold 91 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-15 | Code: M | equity_swap_involved: false | shares_owned_after: 548.00 | transaction_form_type: 4 | Footnotes: F1, F4, F4

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
• F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 26, 2025, with the intent to cover taxes in connection with the vesting of the restricted stock units.
• F3: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
• F4: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
• REMARKS: EVP, Chief Operating Officer